This community trial will recruit 60 secondary schools from across three Local Health Districts (LHDs) within New South Wales (NSW). A two-by-two factorial study design will be used to determine the effect of the Thirsty? Choose Water! behavioural intervention (TCW-BI), and the installation of chilled water stations. The recruited secondary schools will be randomised and non-blinded to one of four study arms receiving either the TCW-BI or chilled water stations, both interventions, or neither (control group). Baseline measures will be collected including student self-report surveys which will gather data regarding knowledge, attitudes and consumption of water and SSBs, a school profile and an environmental scan. Student surveys will be repeated post the intervention and at follow-up. Regular water meter readings will determine the water flow from the chilled water stations across the study period.
There is an increasing body of evidence which suggests that decreasing consumption of SSBs can impact positively on childhood overweight and obesity. However, in the Australian context there are limited studies on how this may occur in the secondary school setting. This study will add to this evidence base and establish the effectiveness of TCW-BI and chilled water stations, either alone or combination on increasing water consumption in adolescents. Information about barriers and facilitators to implementation will be documented. Packages to support the implementation of the TCW-BI as a state-wide initiative will be developed.
Australian and New Zealand Clinical Trials Register ACTRN12618000526279 April 2018.
这项社区试验将从新南威尔士州(NSW)的三个地方卫生局(LHD)招募60所中学。将使用二乘二因子研究设计来确定口渴?选择水!行为干预(TCW-BI)的效果,和冷冻水站的安装。被招募的中学将被随机分配,并且不会对接收TCW-BI或冷冻水站的四个研究小组之一产生影响,两种干预措施,或者都没有(对照组)。将收集基线措施,包括学生自我报告调查,这些调查将收集有关知识的数据,水和SSB的态度和消费,学校简介和环境扫描。学生调查将在干预后和后续行动中重复进行。定期的水表读数将确定整个研究期间来自冷冻水站的水流量。
越来越多的证据表明,减少SSB的消费可以对儿童超重和肥胖产生积极影响。然而,在澳大利亚的背景下,关于中学环境中如何发生这种情况的研究有限。这项研究将增加这一证据基础,并建立TCW-BI和冷冻水站的有效性,单独或组合增加青少年的用水量。将记录有关实施障碍和促进者的信息。将开发支持将TCW-BI作为全州计划实施的软件包。
澳大利亚和新西兰临床试验注册ACTRN12618000526279四月2018。